Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
falimarev
- Development stage
- Phase 2
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Falimarev is a therapeutic cancer vaccine composed of a recombinant fowlpox viral vector encoding the carcinoembryonic antigen (CEA), mucin 1 (MUC1), and TRICOM, which consists of three co-stimulatory molecule transgenes (B7‑1, ICAM‑1, and LFA‑3). The vaccine is designed to enhance the presentation of CEA and MUC1 antigens to antigen-presenting cells, thereby stimulating a cytotoxic T-cell response against tumor cells expressing these antigens. Falimarev has been investigated primarily for use in various cancers including colorectal cancer, metastatic cancer, pancreatic adenocarcinoma, and other solid tumors[2][4][5].
- Brand names
- PANVAC-F
- Other names
- falimarev
02
Targets
CD80 (T-lymphocyte activation antigen CD80)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)ICAM1 (Intercellular Adhesion Molecule 1)CD58 (Leukocyte function-associated antigen 3)MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on falimarev.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on falimarev.